High Internalization ADC
Ovarian Cancer
Key Facts
About Lytica Therapeutics
Lytica Therapeutics is a private, preclinical-stage biotech company founded in 2022, specializing in an innovative ADC platform. Its core technology, the Stapled Internalization Promoter (SIP) platform, uses peptide co-conjugates to dramatically increase antibody internalization into target cells, aiming to improve the potency and therapeutic window of ADCs. The company is developing a pipeline of internal oncology programs targeting solid and hematological tumors and is actively seeking partnerships to leverage its platform externally.
View full company profileAbout Lytica Therapeutics
Lytica Therapeutics is a private, preclinical-stage biotech company founded in 2022, specializing in an innovative ADC platform. Its core technology, the Stapled Internalization Promoter (SIP) platform, uses peptide co-conjugates to dramatically increase antibody internalization into target cells, aiming to improve the potency and therapeutic window of ADCs. The company is developing a pipeline of internal oncology programs targeting solid and hematological tumors and is actively seeking partnerships to leverage its platform externally.
View full company profileAbout Lytica Therapeutics
Lytica Therapeutics is a private, preclinical-stage biotech company founded in 2022, specializing in an innovative ADC platform. Its core technology, the Stapled Internalization Promoter (SIP) platform, uses peptide co-conjugates to dramatically increase antibody internalization into target cells, aiming to improve the potency and therapeutic window of ADCs. The company is developing a pipeline of internal oncology programs targeting solid and hematological tumors and is actively seeking partnerships to leverage its platform externally.
View full company profileAbout Lytica Therapeutics
Lytica Therapeutics is a private, preclinical-stage biotech company founded in 2022, specializing in an innovative ADC platform. Its core technology, the Stapled Internalization Promoter (SIP) platform, uses peptide co-conjugates to dramatically increase antibody internalization into target cells, aiming to improve the potency and therapeutic window of ADCs. The company is developing a pipeline of internal oncology programs targeting solid and hematological tumors and is actively seeking partnerships to leverage its platform externally.
View full company profileTherapeutic Areas
Other Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Ivospemin (SBP-101) | Panbela Therapeutics | Preclinical |
| Yondelis (trabectedin) | PharmaMar | Approved |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| NP-G2-044 + Chemotherapy Agents | Novita Pharmaceuticals | Phase 2a |
| Ovarian Cancer Early Detection Assay | GenEndeavor | Pre-clinical |
| INVAC-1 | Invectys | Phase 2 |
| Folate Receptor-Targeted PCC | Indi Molecular | Preclinical |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Platform Candidate | FLAG Therapeutics | Preclinical |
| Lead ADC Program (Ovarian Cancer) | Medicovestor | Pre-clinical |
| CARG-2020 | CaroGen | Pre-clinical |
| Idetrexed | Algok Bio | Phase 1b |